Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
ImmunityBio Supersedes Expectations With Fivefold Revenue Increase
01:02pm, Wednesday, 25'th Feb 2026
ImmunityBio Inc. (NASDAQ: IBRX) shares are down on Wednesday, cooling off from a huge up move as the company is reportedly experiencing significant revenue growth.
ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate
09:09am, Wednesday, 25'th Feb 2026
Source: Benzinga
Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700%
04:44pm, Monday, 23'rd Feb 2026
On Feb. 23, 2026, investors weighed ANKTIVA's explosive revenue ramp against ImmunityBio's deep losses and ambitious global expansion.
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive
Why ImmunityBio Stock Is Soaring Again Today
12:41pm, Monday, 23'rd Feb 2026
ImmunityBio's sales grew 700% in 2025, with fourth-quarter revenue rising 20% quarter over quarter. These excellent results extend an incredible run of good news for the up-and-coming biotech stock.
ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
12:34pm, Monday, 23'rd Feb 2026
ImmunityBio Inc. (NASDAQ: IBRX) shares are up on Monday following the company's announcement of significant revenue growth.
ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
11:35am, Monday, 23'rd Feb 2026
ImmunityBio (IBRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.15 per share a year ago.
Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More
07:31am, Monday, 23'rd Feb 2026
The Undercovered Dozen series spotlights 12 less-covered stocks highlighted in recent Seeking Alpha articles. This week's edition covers articles published between Feb. 13 and Feb. 19, offering fresh
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approxi
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
08:06pm, Thursday, 19'th Feb 2026
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised
ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average
11:37am, Thursday, 19'th Feb 2026
ImmunityBio Inc (NASDAQ: IBRX) stock is maintaining a confirmed Golden Cross, with the stock now trading roughly 170% above its 200-day moving average — a measurable signal of sustained long-term tr
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
09:00am, Thursday, 19'th Feb 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (n
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up
08:35am, Thursday, 19'th Feb 2026
IBRX wins conditional EU approval for its Anktiva+BCG bladder cancer combo, sending shares soaring 41.9% and expanding its global footprint to 33 countries.
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?
07:05am, Thursday, 19'th Feb 2026
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
